Literature DB >> 100615

Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder.

G J Gavrell, R W Lewis, W L Meehan, G A Leblanc.   

Abstract

Recurrent transitional cell carcinoma was treated with prophylactic intravesical thio-tepa in 22 cases. Group 1 patients were treated with 30 mg. twice daily for the first 3 days postoperatively. Group 2 patients were given additional treatment at increasing intervals indefinitely. Before therapy control patients averaged 1 recurrence every 9.5 months. Group 1 patients averaged 1 recurrence per 33 mpnths. Group 2 patients averaged 1 recurrence per 41 months. Leukopenia occurred in only 2 patients. Thio-tepa can be given safely in the immediate postoperative period and is effective in decreasing the recurrence rate of superficial bladder tumors.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 100615     DOI: 10.1016/s0022-5347(17)57202-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

Review 1.  Intravesical chemotherapy in the United States. An overview.

Authors:  J T Spaulding
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  Prophylactic use of topical adriamycin after transurethral resection of transitional cell bladder tumours.

Authors:  J Flamm; F Grof
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.